Nexpram (Escitalopram)

Escitalopram, the active ingredient in Nexpram, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral dosage form for oral use. It is prescribed for several mood and anxiety disorders in adult patients.

GNH USA supplies Nexpram as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Escitalopram is an SSRI that modulates serotonergic pathways implicated in mood and anxiety disorders.

Major depressive disorder: reduces depressive symptoms and improves overall mood. Generalized anxiety disorder: lessens excessive worry and physical tension. Social anxiety disorder: diminishes fear of social situations and improves functioning. Panic disorder: decreases frequency and intensity of panic attacks.

Escitalopram may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: transient stomach upset, often early in treatment. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects: - Serotonin syndrome: agitation, hyperthermia, muscle rigidity; requires immediate medical attention. - Suicidal thoughts: emergence of new or worsening ideation, especially in young adults. - Hyponatremia: low blood sodium levels, presenting with confusion or weakness.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

Assess for suicidal thoughts: monitor patients, particularly during the first weeks of treatment. Check for electrolyte disturbances: evaluate sodium levels in at‑risk individuals. Review concomitant serotonergic agents: avoid combinations that may precipitate serotonin syndrome. Consider hepatic or renal impairment: dose adjustments may be needed. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Escitalopram can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Pimozide: may cause cardiac arrhythmias. - Triptans: increased potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - NSAIDs or antiplatelet agents: heightened bleeding risk. - CYP2C19 inhibitors (e.g., fluoxetine): may raise escitalopram plasma levels. - Alcohol: can exacerbate central nervous system depression.